Stable Crystalline Forms of BTK Inhibitor Compound 1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing Compound (1), a potent Bruton's Tyrosine Kinase (BTK) inhibitor, face challenges in large-scale manufacturing due to instability in crystalline morphology, leading to quality control issues and potential toxicity from degradation products.
Innovation Solution
The development of stable crystalline forms, specifically Forms 1 and 2, of Compound (1) and its HCl salt, which are characterized by specific XRPD patterns and molecular structures, ensuring consistent processing and pharmaceutical quality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If column chromatography is used to purify Compound (1) on a large scale, then product purity is improved, but manufacturing complexity and cost increase significantly
Solution Approach 1:
The patent extracts and eliminates the need for column chromatography by designing a synthesis route that produces Compound (1) with sufficient purity through crystallization alone. The process removes the complex purification step while maintaining product quality, achieving this by optimizing the crystallization conditions to obtain pure product directly from the reaction mixture.
Solution Approach 2:
The patent changes the physical parameters of the system by introducing specific crystallization conditions (temperature, solvent system, pH control) that enable direct crystallization of pure Compound (1) from the reaction mixture. This parameter optimization allows the product to precipitate in pure form without requiring chromatographic purification.
2Ease of manufacture
If unstable crystalline forms are used during manufacture and storage, then processing is simpler, but product quality and stability deteriorate
Solution Approach 1:
The patent applies preliminary action by pre-converting Compound (1) into its stable crystalline form during the synthesis process itself. The crystallization step is incorporated into the manufacturing process before storage and distribution, ensuring the product is in its most stable form from the outset. This prevents later polymorphic transitions and maintains product quality throughout the supply chain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable crystalline forms of Compound (1) and its HCl salt enhance physical and chemical stability, improve absorption, and ensure shelf-stability, thereby addressing the challenges of large-scale manufacturing and maintaining high pharmaceutical standards.
Implementation Method 1
When a compound crystallizes from a solution or slurry, it may crystallize with different spatial lattice arrangements, a property referred to as 'polymorphism.'
Data Source
AI summary
The present disclosure relates to crystalline forms of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one free base and HCl salt thereof.